Liver Cancer Newswire

Liver Cancer Newswire

Comprehensive Real-Time News Feed for Liver Cancer.

Results 1 - 20 of 3,067 in Liver Cancer

  1. New research shows immunotherapy targeting several cancersRead the original story w/Photo

    2 hrs ago | PhysOrg Weblog

    ... best candidates for these therapies." A small, phase I clinical trial with 42 patients suffering from advanced liver cancer, presented Friday at the conference, showed a reduction of more than 30 percent in tumors in 42 percent of participants with ...

    Comment?

  2. Exclusive interview: Nino Severino, on life without Elena BaltachaRead the original story w/Photo

    4 hrs ago | Sunday Herald

    ... talented woman at 30 be anything but? However it is also inspiring and has not ended with her passing from liver cancer. Baltacha, born in Ukraine but raised in Scotland, endured physical illnesses such as a chronic liver problem and overcame ...

    Comment?

  3. Mthembu, Wostmann SA's Comrades hopefulsRead the original story w/Photo

    5 hrs ago | Iol.co.za

    Organisers of the Comrades Marathon are expecting between 18000 and 19000 runners to line up at the Durban City Hall. Photo: AFP Organisers of the Comrades Marathon are expecting between 18000 and 19000 runners to line up at the Durban City Hall for the 90th anniversary of the greatest ultra-marathon of them all.

    Comment?

  4. Global Hepatitis B Vaccines market to grow at a CAGR of 4.00% During 2015Read the original story w/Photo

    Jan 4, 2015 | Medgadget

    ... significant consequences. The chronic form of infection, in some cases, can progress up to cirrhosis and liver cancer. Hepatitis B infection can be prevented by immunization with hepatitis B vaccines. This report covers the present scenario and the ...

    Comment?

  5. Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb's PD-1 ...Read the original story

    18 hrs ago | Information Technology

    Phase I/II Opdivo Trial Shows Bristol-Myers Squibb's PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma announced results from an interim analysis of CA209-040, a Phase I/II dose-ranging trial evaluating the safety and anti-tumor activity of Opdivo in previously-treated patients with hepatocellular carcinoma or advanced liver cancer. Initial findings demonstrated that the estimated survival rate in evaluable patients was 62% at 12 months.

    Comment?

  6. ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer TypesRead the original story w/Photo

    21 hrs ago | TheStreet.com

    ... a newly discovered genetic biomarker. The tumor response rate to Bristol's Opdivo in patients with advanced liver cancer was 19%. The overall survival rate at 12 months was 62%. While early, the results suggest Opdivo may have a role to play in the ...

    Comment?

  7. Provectus Biopharmaceuticals Inc.??? Abstract On Liver Cancer Accepted For Poster Presentation AtRead the original story

    Thursday | BioSpace

    Provectus Biopharmaceuticals, Inc. , a clinical-stage oncology and dermatology biopharmaceutical company , announced today that the organizing committee of the 6th Asia-Pacific Primary Liver Cancer Expert Meeting has accepted the Company's abstract "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver", for a poster presentation.

    Comment?

  8. Missiona Read the original story w/Photo

    Yesterday | The Courier

    ... the Scott family. It has been less than a year since the mother of two was diagnosed with stage-four bowel and liver cancer. Mrs Scott was recently put on slow-release chemotherapy to improve her quality of life for her husband Ben and children ...

    Comment?

  9. New Products Will Propel Bayer HigherRead the original story w/Photo

    Yesterday | Seeking Alpha

    ... scope of Xarelto's utility, the more sales the drug will generate. Stivarga is being tested as a treatment for liver cancer. Bayer's strategy is to find more uses for its existing portfolio of pharmaceuticals. Xarelto is an anticoagulant that has ...

    Comment?

  10. Can-Fite BioPharma reports Q1 2015 financial results, provides updates on drug development programsRead the original story w/Photo

    Yesterday | Medical News

    ... trial is expected to be completed during the second half of 2015. CF102 Enrolling and Dosing Patients in Liver Cancer Trial Can-Fite continues to enroll and dose patients in its global Phase II liver cancer study. Approximately 78 patients are ...

    Comment?

  11. Just Published: "KAHR medical Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile"Read the original story

    Yesterday | PR-inside.com

    ... KAHR-102, and KAHR-103. Its KAHR-101 is a fusion-protein used for the treatment in animal disease models for liver cancer, renal cancer, multiple sclerosis and rheumatoid arthritis; and KAHR-102 is a fusion protein that links portions of two immune ...

    Comment?

  12. Ombitasvir/paritaprevir/r in hepatitis C: Indication of added benefit in certain patientsRead the original story

    Yesterday | Medical News Today

    ... It remained unclear in how many patients in whom the virus is no longer detectable, late complications, and liver cancer in particular, can actually be prevented. For the first time in the assessment of a hepatitis C drug, the manufacturer dossier ...

    Comment?

  13. Cancer second largest killer in India: ReportRead the original story w/Photo

    Yesterday | DNA India

    ... diagnosed with cancer, and there were 8.2 million deaths worldwide. The study also says that lung, stomach and liver cancer were the leading causes of death in women and men around the world.

    Comment?

  14. Liver Cancer-Identifying and Commercializing Market Size, Share,...Read the original story

    Yesterday | PR-inside.com

    The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market.

    Comment?

  15. Weaker dollar, banks helps ASX end May in the blackRead the original story w/Photo

    Yesterday | The Age

    ... month James Hardie lifted 24 per cent, Sirtex Medical 20 per cent - after good results from a drug trial for liver cancer - and GUD Holdings 18 per cent, after it unveiled plans to buy lighting products supplier Brown & Watson International. Worst ...

    Comment?

  16. GM bacteria 'sensors' could detect cancer, diabetesRead the original story w/Photo

    Yesterday | Russia Taday

    ... diabetes was present when in fact it was not in just 3 percent of cases. The study's researchers are working on liver cancer at the Massachusetts Institute of Technology and UC San Diego, and diabetes at University of Montpellier in France and ...

    Comment?

  17. Stocks to watch on FridayRead the original story w/Photo

    Yesterday | NEWS.com.au

    ... Sirtex have been placed in a trading halt ahead of the release of new information about a clinical trial of its liver cancer treatment.

    Comment?

  18. Lemon scent found to slow development of liver cancerRead the original story w/Photo

    Yesterday | NewsTarget.com

    A recent study from experts at Ruhr-University Bochum suggests that the olfactory receptor could be a beneficial way to hone in on liver cancer diagnosis and therapy. In particular, they've eyed the monoterpene citronell as possible way to identify and treat cancerous liver cells.

    Comment?

  19. When Your Dog DiesRead the original story w/Photo

    Yesterday | Psychology Today

    ... most part, they don't complain. Toby skirted death a number of times in recent years. He survived surgery for liver cancer. When his vocal cord was later tied back and he lost his ability to bark, he tried all his might regardless-even though the ...

    Comment?

  20. Banks lead Aust market higherRead the original story

    Yesterday | Yahoo!

    ... group Sirtex was in a trading halt ahead of the release of new information about a clinical trial of its liver cancer treatment. Sirtex last traded at $26.68. On Wall Street in the US on Thursday, stocks dipped, following leading euro zone equity ...

    Comment?